Insight Molecular (NASDAQ:IMDX) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.24) by 13.92 percent. This is a 3.57 percent increase over losses of $(0.28) per share from the same period last year. The company reported quarterly sales of $1.139 million which beat the analyst consensus estimate of $290.000 thousand by 292.76 percent. This is a 23.35 percent decrease over sales of $1.486 million the same period last year.